Chardan Capital Raises SAB Biotherapeutics Buy Rating to $12 from $11.

lunes, 17 de noviembre de 2025, 7:17 am ET1 min de lectura
SABS--

Chardan Capital Raises SAB Biotherapeutics Buy Rating to $12 from $11.

Chardan Capital Raises SAB Biotherapeutics Buy Rating to $12 from $11.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios